Absci stock surges 24% on positive Phase 1 hair loss drug data Investing.com South Africa
Absci stock surges 24% on positive Phase 1 hair loss drug data By Investing.com Investing.com India
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) The Manila Times
Absci Reports Positive Phase 1 Results for ABS-201, a First-in-Class PRLR Antibody for Hair Regrowth and Endometriosis – Minichart Minichart
Taking the combined oral contraceptive pill can increase binge eating, study suggests MSN
Catheter-Based OCT May Help ID Early Endometrial Cancer Ophthalmology Advisor
Endometriosis (EMs) is a prevalent gynecological disorder affecting reproductive-age women. Exosomes secreted by peripheral blood macrophages may participate in EMs progression. In this pilot translational study, exosomes from peripheral blood …
Endometriosis is a chronic inflammatory condition affecting 10% to 15% of reproductive-aged women. The urinary tract is the second most common extragenital site of endometriosis after the gastrointestinal tract, with …
Endometriosis (EM) is a common gynecological disorder imposing a considerable burden on the quality of life of women through chronic pain, infertility, and other clinical manifestations. The effectiveness of management …
Spontaneous ovarian endometrioma rupture typically presents with acute abdominal pain, a condition often complicated by tissue edema and pelvic adhesions that increase surgical difficulty. This study aims to evaluate the …